English press releases

Gilead Announces Latest Data in Ongoing HIV Cure Research Program

– New Studies Evaluate Agents with Potential Role in Eliminating HIV Viral Reservoir – FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) today presented...

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200...

Wealthy Americans are increasingly willing to invest, new UBS survey finds

NEW YORK–(BUSINESS WIRE)– US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs...

Experiments Demonstrate Seoul Semiconductor SunLike Series Natural Spectrum LEDs Enhance Crop Yields, Antioxidant Content

Experiments show that crops grow faster, larger, and with better nutritional content when grown under SunLike Series LEDs compared to standard white LEDs ANSAN, South...

Seoul Semiconductor Switches to Rimini Street for SAP Support

Leading global LED manufacturer avoids forced migration to SAP S/4HANA product, achieves significant cost savings and receives more robust, responsive support LAS VEGAS–(BUSINESS WIRE)– Rimini...

Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market

LONDON–(BUSINESS WIRE)– Luminati, the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it...

Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth

LAUSANNE, Switzerland & NEWARK, Calif.–(BUSINESS WIRE)– Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2020. This...

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching...

Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV

– Phase 1b Study Demonstrates Potent Antiviral Efficacy Following a Single Subcutaneous Injection of GS-6207, No Discontinuations Due to Adverse Events – FOSTER CITY, Calif.–(BUSINESS...

Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease

Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) OSAKA,...

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

OTEZLA reduced the number and pain of oral ulcers in the 12-week placebo-controlled Phase 3 RELIEF™ study With this third indication in the U.S., OTEZLA...

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with...

Business Figures for the First Half of 2019: Sartorius Continues Double-digit Growth

Group revenue up 15.9%; order intake up 18.7%; earnings margin 26.6% High growth dynamics in the Bioprocess Solutions Division; moderate development of the Lab Products...

Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) today announced that new data from the company’s HIV research and development programs will be presented...

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

Boehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases...